#United States #Aurora #cystic fibrosis #Children's Hospital Colorado #Prenatal Treatment

Transforming Cystic Fibrosis Care: The Role of Prenatal Treatment

This Cystic Fibrosis Awareness Month, the spotlight shines on Children's Hospital Colorado (Children's Colorado), known for its groundbreaking approach to cystic fibrosis (CF) treatment starting before birth. This innovative strategy aims to improve the long-term health outcomes for children diagnosed with this genetic disorder, which affects the lungs and digestive system.

A Multidisciplinary Approach

Located in Aurora, Colorado, Children's Colorado is leading the way in offering multidisciplinary care to families facing a cystic fibrosis diagnosis. Through the collaborative efforts of the Breathing Institute and the Colorado Fetal Care Center, the hospital has successfully provided prenatal therapy to ten families whose unborn children were exhibiting early signs of cystic fibrosis. This early intervention is not only unique to the United States but positions Children's Colorado among the world’s most experienced healthcare providers in this area.

The initiative to start treatment before birth is transformative. It is focused on providing a comprehensive care plan that not only addresses the immediate needs of the unborn child but also seeks to improve their overall health as they grow. Historically, babies born with meconium ileus—a serious bowel obstruction often linked to cystic fibrosis—required immediate surgical intervention post-birth. However, with early prenatal treatment at Children's Colorado, these critical blockages have been resolved prior to delivery, and subsequent hospital stays have been reduced considerably.

How Prenatal Treatment Works

Cystic fibrosis is caused by mutations in the CFTR gene, which leads to the production of thick, sticky mucus that obstructs pulmonary function and nutrient absorption. Treatment typically involves a combination of therapies aimed at mitigating these symptoms.

One such innovative therapy is ETI therapy—a cystic fibrosis transmembrane conductance regulator modulator that combines three medications to promote better salt and water movement across cell membranes. This therapy has shown promise in improving lung function and digestive health for those diagnosed with CF. Children’s Colorado is breaking ground by ensuring that this therapy is accessible during pregnancy, allowing parents to take proactive steps in managing their child’s health before birth.

Dr. Michael Zaretsky, director of research at the Colorado Fetal Care Center, emphasizes the profound implications of this approach. “Prenatal treatment offers families unprecedented options. Instead of waiting for symptoms to arise postnatally, we can begin supporting the baby's health earlier and partner with families throughout the process.”

Benefiting From Early Intervention

Studies indicate that prenatal exposure to treatment significantly supports healthier cellular function during crucial developmental windows, particularly concerning lung health. Babies who were treated prenatally exhibited lower sweat chloride levels—a critical indicator of lung function linked to future health outcomes. Continuing treatment postnatally is essential, as it can help sustain the health gains achieved before birth, especially during the delicate early months of life.

As Dr. Jordana Hoppe, medical director of the pulmonary clinic at Children's Colorado, notes, “In cystic fibrosis, early lung damage can begin in infancy. With ETI therapy, we can change the paradigm from reactive care to preventative care, opening the door to potential lifelong health benefits.” Additionally, as a significant advantage, ETI therapy can be transmitted through breast milk, ensuring continuity of care and treatment from mother to child.

A New Care Model

Approximately 1,000 new cases of cystic fibrosis are diagnosed in the United States each year, with a significant percentage detected within the first two years of life. The nature of cystic fibrosis demands that intervention occurs as early as possible, as disease severity can escalate rapidly over time. Children’s Colorado’s groundbreaking prenatal ETI therapy demonstrates an innovative care model that stands to benefit families facing this genetic disorder.

As an institution dedicated to enhancing pediatric healthcare, Children's Hospital Colorado continues to champion research and collaboration focused on improving clinical experiences and outcomes for patients. It has established itself as a leader in advancing care for children with cystic fibrosis and remains committed to furthering these groundbreaking efforts in partnership with families and healthcare systems nationwide.

About Children's Hospital Colorado

Children's Hospital Colorado has been a trusted name in pediatric healthcare since its founding in 1908. Recognized repeatedly as one of the nation's top children's hospitals by U.S. News & World Report, it is dedicated to providing comprehensive, family-centered medical care across its numerous facilities in Colorado. For more information, parents and guardians are encouraged to explore the hospital's resources at www.childrenscolorado.org or connect with them through social media platforms like Facebook, Instagram, and YouTube.